TABLE 1.
Baseline characteristics of participants
| Characteristics | Responder (N = 66) | Nonresponder (N = 117) | P |
|---|---|---|---|
| Age at transplant (y) | 45.5 ± 14.4 | 42.8 ± 16.2 | 0.25 |
| Preemptive transplant, n (%) | 16 (24) | 25 (21) | 0.20 |
| Male, n (%) | 38 (58) | 81 (69) | 0.11 |
| Nonwhite, n (%) | 16 (24) | 36 (31) | 0.35 |
| Cause of ESKD, n (%) | 0.87 | ||
| Diabetes | 10 (15) | 16 (14) | |
| Hypertension | 6 (9) | 15 (13) | |
| Glomerular disease | 23 (35) | 42 (36) | |
| Other | 27 (41) | 44 (38) | |
| Living donor, n (%) | 26 (39) | 36 (31) | 0.24 |
| Previous transplant, n (%) | 16 (24) | 33 (28) | 0.56 |
| Mean HLA mismatch (of 6) | 3.9 ± 1.4 | 4.0 ± 1.4 | 0.88 |
| Induction agent, n (%) | 0.63 | ||
| Antithymocyte globulin | 25 (38) | 37 (32) | |
| Alemtuzumab | 5 (8) | 14 (12) | |
| IL-2 inhibitor | 30 (46) | 58 (50) | |
| Other/none/unknown | 6 (9) | 8 (7) | |
| Indication for the index biopsy, n (%) | |||
| Protocol | 20 (30) | 41 (35) | 0.54 |
| For cause | 46 (70) | 77 (65) | |
| Interval from transplant to index biopsy (mo) | 87.5 ± 93.9 | 80.9 ± 71.9 | 0.59 |
| Interval from index biopsy to follow-up biopsy (d) | 102.0 ± 31.6 | 93.5 ± 28.9 | 0.07 |
| Interval from index biopsy to last follow-up (mo) | 41.2 ± 16.3 | 38.3 ± 17.2 | 0.27 |
| DCGF within 1 y of index biopsy | 3 (5) | 5 (4) | 0.93 |
| Uncensored graft failures at last follow-up (%) | 19 (29) | 55 (47) | 0.02 |
| DCGF at last follow-up (%) | 11 (20) | 41 (39) | 0.02 |
Bold values indicate statistically significant value with P <0.05.
DCGF, death-censored graft failure; ESKD, end-stage kidney disease; IL-2, interleukin 2.